Skyrizi® Pre-filled Cartridge with Injector

What Skyrizi® Is and How It Works

The Skyrizi pre-filled cartridge with on-body injector is a biologic designed for immune-mediated conditions. It helps adults maintain control of Crohn’s disease or ulcerative colitis, and the brand is also approved for plaque psoriasis and psoriatic arthritis with other presentation types. Offered from Canada with US delivery from Canada, it provides access to Canadian pricing that many cash-pay patients without insurance explore.

CanadianInsulin is a prescription referral service. We verify your prescription with your clinic, and licensed Canadian pharmacies dispense your order.

Skyrizi® contains risankizumab, a monoclonal antibody targeting the p19 subunit of interleukin‑23 (IL‑23). By selectively blocking IL‑23 signaling, it helps calm overactive immune responses that drive skin plaques, joint inflammation, and inflammatory bowel disease. The pre-filled cartridge is loaded into a single-use on-body injector designed to deliver the full subcutaneous maintenance dose automatically after activation.

The on-body injector adheres to intact skin and delivers medication through a small hidden needle. The device adds convenience for maintenance therapy and is used after a healthcare provider initiates treatment and provides training on the instructions for use.

Who Skyrizi® Is For

Indications include adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis. The pre-filled cartridge with injector is used for maintenance dosing in inflammatory bowel disease following induction therapy administered by a healthcare professional. For skin and joint indications, maintenance is typically given with a prefilled pen or syringe presentation.

Patients with active, clinically significant infections should not start until the infection resolves. Tuberculosis screening is recommended before the first dose. Use caution in those with recurrent infections, chronic infections, or conditions that affect immune function. Live vaccines should be avoided during treatment. Pediatric use may differ by indication; follow the approved label and clinician guidance for age appropriateness.

For condition-specific browsing and educational content, see our categories for Crohns Disease, Plaque Psoriasis, and Psoriatic Arthritis.

Dosage and Usage

Skyrizi therapy is started by a clinician who selects the induction and maintenance plan for each indication. In inflammatory bowel disease, therapy typically begins with provider-administered induction, followed by home maintenance dosing using the pre-filled cartridge and on-body injector at regular intervals. For plaque psoriasis and psoriatic arthritis, maintenance is generally administered subcutaneously on a less frequent schedule with a prefilled pen or syringe.

Training on the device is important. The on-body injector is applied to clean, dry, intact skin on a recommended site and activated per the instructions for use. The device adheres to the skin and automatically delivers the full dose; a status indicator and audible or visual signals are commonly used to confirm completion. Do not attempt to re-use the device. If any part of the device is damaged, do not use it and contact the pharmacy or prescriber for next steps.

If therapy is interrupted, the prescriber will advise whether and when to resume. Always follow the patient Medication Guide and Instructions for Use that accompany the product for step-by-step handling details.

Strengths and Forms

• Pre-filled cartridge with on-body injector: single-use cartridge supplied with a single-use injector for maintenance dosing in Crohn’s disease and ulcerative colitis. The labeled maintenance dose commonly used with the cartridge is 360 mg at set intervals.
• Prefilled pen or prefilled syringe: commonly supplied as 150 mg for plaque psoriasis and psoriatic arthritis maintenance schedules.
• Intravenous induction formulation: provider-administered infusions for certain IBD indications before transitioning to subcutaneous maintenance.

Availability may vary by presentation. The specific product supplied will match the strength and form on the valid prescription.

Missed Dose and Timing

If a maintenance dose is missed, administer as soon as feasible and then follow the regular schedule from the new date or as advised by the prescriber. If the next dose is already near, the prescriber may suggest adjusting to maintain consistent spacing. Do not double up to make up for a missed dose.

Storage and Travel Basics

Store refrigerated in the original carton to protect from light. Do not freeze, and do not shake. When preparing to use, allow the carton to reach room temperature out of direct sunlight. Keep the injector and cartridge dry until application. If the product has been left out longer than label guidance or appears damaged, contact the pharmacy before use.

For travel, keep the medicine cool with a suitable insulated pack and avoid temperature extremes. Carry the original label and prescription details for security screening. Temperature-sensitive items ship with cold-chain handling and insulated packaging.

Pen Handling and Sharps Disposal

Although this is an on-body injector rather than a pen, the same safety principles apply. Do not share injection devices. Use only once and discard. If a separate needle or any sharp component is exposed, dispose of it immediately in a puncture-resistant sharps container. Follow local or state guidance for medication device disposal; never place sharps loose in household trash. Keep used and unused devices out of reach of children and pets.

Benefits

• Targeted IL‑23 inhibition that addresses a key inflammatory pathway in psoriasis, psoriatic arthritis, and IBD.
• Proven efficacy in skin clearance, joint symptom improvement, and IBD remission maintenance as shown in pivotal trials.
• Infrequent maintenance dosing schedules that can reduce treatment burden compared with many older biologics.
• Home administration option with an on-body injector for IBD maintenance after induction.
• Consistent dosing and device design that can support adherence for long-term disease control.

Side Effects and Safety

• Common: upper respiratory infections, headache, fatigue, injection site reactions, tinea or other mild fungal infections, and gastrointestinal symptoms such as nausea.
• Less common: elevated liver enzymes, urinary tract infection, or general malaise.

Serious risks include severe infections, opportunistic infections, and hypersensitivity reactions. Tuberculosis reactivation can occur; screen prior to treatment and monitor during therapy. If signs of infection, allergic reaction, or other concerning symptoms develop, treatment may need to be paused while a clinician evaluates the cause. This medicine affects immune response; risk can be higher when combined with other immunosuppressants.

Drug Interactions and Cautions

Skyrizi is a biologic targeting an immune pathway and is not known for cytochrome P450–mediated drug interactions. The primary concerns relate to immune function and vaccination.

• Avoid live vaccines while on therapy; discuss timing of non-live vaccines with a clinician.
• Use caution with concurrent immunosuppressive agents; infection risk may be additive.
• Screen for tuberculosis and consider hepatitis B risk assessment based on history.
• Inform clinicians of any history of recurrent infections or chronic conditions that weaken immune defenses.

For additional context on mechanism differences among biologics, see our overview comparing related agents such as Stelara Pre Filled Syringe and Humira, and read the article Ustekinumab Vs Adalimumab.

What to Expect Over Time

Skin, joint, or gastrointestinal symptoms typically improve gradually as inflammation decreases. Some patients notice early changes, while others observe steadier gains through continued maintenance. The goal is durable disease control with a predictable schedule. If response is suboptimal, clinicians may adjust dosing presentation or consider alternatives with a different target.

Compare With Alternatives

Biologic options differ by target and dosing. Ustekinumab blocks IL‑12 and IL‑23 and is offered as a Stelara Pre Filled Syringe after an initial infusion for IBD, with skin and joint indications as well. Adalimumab is a TNF inhibitor available as Humira, commonly dosed more frequently than IL‑23 agents. Choice depends on prior therapies, comorbidities, and individual response.

Pricing and Access

Many patients choose cross-border fulfillment to benefit from Canadian pricing on brand biologics. With a valid prescription, orders are verified and dispensed by licensed Canadian pharmacies. This can provide meaningful savings compared with typical US cash-pay costs. If using insurance, follow the plan’s rules; if paying cash, multi-month fills may lower per-dose costs and reduce delivery fees.

We support prompt, express, cold-chain shipping and provide status updates once the order is processed. Looking for current offers or news on seasonal deals? Visit our promotions page.

Availability and Substitutions

Product availability can vary by presentation and supply. If the exact cartridge-and-injector kit is temporarily unavailable, a prescriber may recommend a suitable alternative presentation or an evidence-based alternative biologic, when clinically appropriate. Pharmacy teams coordinate any substitution only with prescriber approval.

Patient Suitability and Cost-Saving Tips

• Good candidates include adults with approved indications who have completed infection screening and do not have active serious infections.
• Use caution in those with a history of recurrent infections or conditions that increase infection risk.
• Ask about aligning refill dates and choosing a multi-month quantity to reduce delivery charges.
• Set reminders to support on-time maintenance dosing and avoid gaps in therapy.
• Keep an updated medication list to share with clinicians during checkups.

Questions to Ask Your Clinician

• Is the on-body injector cartridge the right maintenance presentation for my condition?
• How should I prepare and apply the device safely at home?
• What signs of infection or allergic reaction require evaluation before the next dose?
• Should I update non-live vaccines before treatment or between doses, and avoid live vaccines entirely?
• How will my response be monitored over time, and what are the options if goals are not met?
• Are there lab tests or screenings needed before and during therapy?

Authoritative Sources

• Skyrizi US Prescribing Information
• FDA Drug Label Database Entry
• Crohn’s & Colitis Foundation Medication Guide

Ready to request your prescription with confidence? Place your Skyrizi order through CanadianInsulin for prompt, express, cold-chain shipping and US delivery from Canada.

Disclaimer: This information is for general educational purposes and does not replace the advice of a licensed clinician. Always follow the approved label and your prescriber’s guidance for diagnosis, treatment, and dosing.